ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer

• Status: Completed
• Trial end date: 2017-03-07

Summary

The primary objective of this study is to compare the effect of panitumumab versus cetuximab on overall survival (OS) for chemorefractory metastatic colorectal cancer (mCRC) among patients with wild-type Kirsten rat Sarcoma-2 virus (KRAS) tumors.

• Phase: Phase 3

Details

• Lead Sponsor: Amgen
• Treatments: Antibodies, Monoclonal; Cetuximab; Panitumumab